Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 24, 2024
Daily News
September 24, 2024
- NHI-Market Price Gap on Narrowing Trend, but Results Remain Unpredictable
September 24, 2024
- NIBIOHN, Institut Pasteur Link Arms in Drug, Vaccine Research
September 24, 2024
- More Pregnant Cases Reported for COVID Meds, Panel Urges Greater Caution
September 24, 2024
- Japan’s 1st CGP Assay for Blood Cancer Approved: Otsuka
September 24, 2024
- Tsumura to Cover Return Costs for China Staff after Shenzhen Stabbing
September 24, 2024
- Ultragenyx’s Gene Therapy in Line for Orphan Tag in Japan
September 24, 2024
- Orphan Status Granted to Sanofi’s Venglustat and More in Japan
September 24, 2024
- Japan Pulls Sakigake Tags from Olumiant, Xevinapant
September 24, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…